✉ Email this page to a colleague
« Back to Dashboard
Atrasentan is an investigational drug.
There have been 20 clinical trials for Atrasentan. The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2001.
The most common disease conditions in clinical trials are Kidney Diseases, Prostatic Neoplasms, and Diabetic Nephropathies. The leading clinical trial sponsors are Abbott, AbbVie (prior sponsor, Abbott), and National Cancer Institute (NCI).
Recent Clinical Trials for Atrasentan
|Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy||Chinook Therapeutics, Inc.||Phase 2|
|Atrasentan in Patients With Proteinuric Glomerular Diseases||Chinook Therapeutics U.S., Inc.||Phase 2|
|Atrasentan in Patients With IgA Nephropathy||Chinook Therapeutics U.S., Inc.||Phase 3|